ncRNA basic information ncRNA ID: ENSG00000248092 ncRNA Database: Ensembl ncRNA Name: NNT-AS1 ncRNA Type: lncRNA ncRNA Expression: up-regulated ncRNA Method: qRT-PCR ncRNA Target Gene: NA ncRNA Pathway: MAPK/Slug pathway Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB00515 (APRD00359) Drug Name: Cisplatin Drug Method: Fluorescence quantitative Real-time polymerase chain reaction (qRT-PCR) was used to detect the expression levels of lncRNA NNT-AS1 in NSCLC cell lines (A549 and SPCA-1) and DDP-resistant cell lines (A549/DDP and SPCA-1/DDP). Corresponding plasmids of si-NTT-AS1 and si-NC were conducted. Then, methyl thiazolyl tetrazolium (MTT) assay was applied to detect the changes in half inhibition concentration (IC50) values of DDP in A549/DDP and SPCA-1/DDP cells after interference in lncRNA NNT-AS1 expression. Clone formation assay and flow cytometry were employed to detect the changes in proliferation, cycle and apoptosis of A549/DDP and SPCA-1/DDP cells caused by si-NNT-AS1. Protein expressions of molecular markers in mitogen-activated protein kinase (MAPK)/Slug signaling pathway after interference in lncRNA NNT-AS1 expression was detected by Western blotting. The differential expressions of lncRNA NNT-AS1 in 10 pairs of drug-resistant and non-resistant tissues were detected by qRT-PCR. Drug Response: resistant

Cancer basic information Cancer: lung non-small cell carcinoma Tissue/Cell: cell line (A549, SPCA-1,A549/DDP and SPCA-1/DDP)

Other information Title: LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway. Journal: Eur Rev Med Pharmacol Sci Published: 2018 PubMed ID: 30070323